Literature DB >> 16500515

Resting blood pressure and bone mineral content are inversely related in overweight and obese Hispanic women.

Afrooz Afghani1, C Anderson Johnson.   

Abstract

BACKGROUND: Previous studies have shown that hypertension is related to abnormalities of calcium metabolism such as increased calcium losses from kidney and secondary activation of parathyroid glands. In animal studies, high blood pressure (BP) has been shown to increase the risk of bone mineral loss; however whether hypertension is associated with reduced bone mineral content (BMC) in human beings is inconclusive. The relationship between BP and BMC has not been previously studied in Hispanic individuals.
METHODS: Total body BMC of 33 overweight and obese (mean BMI= 31.1 kg/m(2)) premenopausal Hispanic women 22 to 51 years of age from Los Angeles, CA, was measured using dual-energy x-ray absorptiometry. Seated systolic BP (SBP) and diastolic BP (DBP) were measured using a standard mercury sphygmomanometer.
RESULTS: Partial correlations revealed an inverse relationship among BMC and SBP (r = -0.61, P < .001), DBP (r = -0.52, P < .01), and hypertension (r = -0.69, P < .0001). In multiple linear regressions, SBP was negatively related (beta = -0.31, P = .001) to BMC and explained 10% of the variance. The DBP did not make a significant contribution to the variance. When fat mass and fat-free mass were controlled for, hypertensive women (n = 9) had significantly lower BMC (2119 g v 2441 g; P < .0001) than normotensive women (n = 23).
CONCLUSIONS: These results reveal that BMC is partially and inversely correlated with resting SBP and DBP in premenopausal Hispanic women; in addition hypertensive women have lower adjusted means of BMC than normotensive women. Sustained hypercalciuria and ensuing hyperparathyroidism as consequences of high BP may be the mechanisms that explain the pathophysiology of increased bone mineral loss in hypertension.

Entities:  

Mesh:

Year:  2006        PMID: 16500515     DOI: 10.1016/j.amjhyper.2005.10.024

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  7 in total

1.  Conducting telephone interviews with community-dwelling older adults in a state Medicaid program: differences by ethnicity and language preference.

Authors:  Melissa A Clark; Michelle L Rogers; Susan M Allen
Journal:  J Health Care Poor Underserved       Date:  2010-11

2.  Bone mass loss is associated with systolic blood pressure in postmenopausal women with type 2 diabetes in Tibet: a retrospective cross-sectional study.

Authors:  L Zhou; J Song; S Yang; S Meng; X Lv; J Yue; A Mina; B Puchi; Y Geng; L Yang
Journal:  Osteoporos Int       Date:  2017-02-02       Impact factor: 4.507

3.  Effect of Primary Hypertension on Treatment Outcomes of Patients with Postmenopausal Osteoporosis: A 5 Year Follow Up Retrospective Study.

Authors:  Volkan Yilmaz; Ebru Umay; Ibrahim Gundogdu; Fatma Aytul Cakcı
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-11-22

4.  Lower bone mineral content in hypertensive compared with normotensive overweight Latino children and adolescents.

Authors:  Afrooz Afghani; Michael I Goran
Journal:  Am J Hypertens       Date:  2007-02       Impact factor: 2.689

5.  A cross-sectional study to evaluate the associations between hypertension and osteoporosis in Chinese postmenopausal women.

Authors:  Jin Zhang; Keqin Zhang; Haiming Shi; Zihui Tang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  Relationship between blood pressure levels and bone mineral density in postmenopausal Turkish women.

Authors:  Selma Yazici; Mehmet Yazici; Ugur Korkmaz; Melih Engin Erkan; Ali Erdem Baki; Ismail Erden; Hakan Ozhan; Safinaz Ataoğlu
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

7.  Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.

Authors:  F de Vries; P C Souverein; C Cooper; H G M Leufkens; T P van Staa
Journal:  Calcif Tissue Int       Date:  2007-02-02       Impact factor: 4.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.